Article

Primary platinum resistance and immune exclusion in ovarian carcinomas with high expression of the homologous recombination mediator RAD51

2020-06-09

Abstract excerpt

<h4>Background</h4> Homologous recombination deficiency (HRD) in ovarian cancer confers increased sensitivity to Poly-ADP-Ribose-Polymerase (PARP) inhibitors and platinum. The homologous recombination (HR) mediator RAD51, however, is commonly overexpressed, potentially driving unregulated HR. Due to non-quantitative measurements and heterogeneous cohorts, the clinical relevance of RAD51 expression in ovarian canc...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: a6ecc0cc-441f-594f-bbd5-1230940336e8
DOI: 10.1101/2020.06.09.137612

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Primary platinum resistance and immune exclusion in ovarian carcinomas with high expression of the homologous recombination mediator RAD51DOI 10.1101/2020.06.09.137612Read

Quantitative imaging of RAD51 expression as a marker of platinum resistance in ovarian cancerSemantic proximity Read

High RAD51 Gene Expression is Associated with Aggressive Biology and with Poor Survival in Breast CancerSemantic proximity Read

Identification of RAD51 foci in cancer-associated circulating cells of patients with high-grade serous ovarian cancer: association with treatment outcomesSemantic proximity Read

Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient StratificationSemantic proximity Read

RAD51 Is Implicated in DNA Damage, Chemoresistance and Immune Dysregulation in Solid TumorsSemantic proximity Read

Combining Homologous Recombination-Deficient Testing and Functional RAD51 Analysis Enhances the Prediction of Poly(ADP-Ribose) Polymerase Inhibitor SensitivitySemantic proximity Read

Predictive value of RAD51 on the survival and drug responsiveness of ovarian cancerSemantic proximity Read

Targeting RAD51-Mediated Homologous Recombination as a Treatment for Advanced Solid and Hematologic Malignancies: Opportunities and Challenges AheadSemantic proximity Read

Functional Homologous Recombination Assay on FFPE Specimens of Advanced High-Grade Serous Ovarian Cancer Predicts Clinical Outcomes.Semantic proximity Read

RAD51 as an immunohistochemistry-based marker of poly(ADP-ribose) polymerase inhibitor resistance in ovarian cancerSemantic proximity Read

RAD51 and PALB2 in precision oncology: Clinical implications for HRD associated breast and ovarian cancers (Review)Semantic proximity Read

A Functional Homologous Recombination Assay Predicts Primary Chemotherapy Response and Long-Term Survival in Ovarian Cancer Patients.Semantic proximity Read